Late results of bioprosthetic tricuspid valve replacement in Ebstein’s anomaly

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

“…The largest North American experience comes from a single institution, the Mayo Clinic, and because of the risk of acute thrombotic complications, particularly in the presence of decreased right ventricular function, Mayo Clinic reports using anticoagulation with VKAs for 3 to 6 months after tricuspid valve replacement with a bioprosthetic valve (target INR, 2-3; in addition, all patients receive aspirin). [330][331][332] It is probably reasonable to assume that patients with other diagnoses undergoing tricuspid valve replacement with a bioprosthetic valve would also benefit from short-term anticoagulation. Mechanical valves have occasionally been used for replacement of the tricuspid valve, but reports in the pediatric age group or even isolated to CHD are rare.…”

Surgical Management of Ebstein’s Anomaly with Atrial Septal Defect in a Young Lady: A Case Report

“…12 Another study showed excellent durability in 158 patients who received a primary tricuspid bio-prosthesis due to unfavorable tricuspid morphology for repair. 13 A comparative study between mechanical and bio-prosthetic heart valve on 333 patients who required a valve replacement, showed superior late survival with those who received porcine bio-prosthesis. 14 In our setting, we performed replacement of the defective TV with St Jude Medical Epic porcine bio-prosthetic heart valve with plication of atrialized portion of right ventricle and direct closure of the ASD.…”

A técnica do cone para correção da anomalia de Ebstein: resultados imediatos e em longo prazo

“…Regarding the tricuspid valve replacement in Ebstein's anomaly, Kiziltan et al 19 reviewed their series of 323 patients with tricuspid valve replacement performed in 48.9% of patients. In the long-term results, 97.5% of patients were free of bioprosthetic valve replacement after five years, and 80.6% after 10 years.…”

“…This technique, which includes transversal plication of the atrialized portion of the RV, results in a tricuspid valve formed by a single leaflet (monocusp) coapted to the interventricular septum. However, the need to have a large and mobile anterior valve to achieve the objective of correcting right AV regurgitation limits this operation to a restrict group of anatomical variations, which require tricuspid valve replacement in 36% to 65% of cases [3][4][5] .…”